You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Company will be hosting a virtual Investor Day on Tuesday, October 20th from 11:00 a.m. ET to approximately 1:00 p.m. ET. Presenting during the event will be: Ligands company presentations will include the following topics: In addition, Dr. Matthew Davis, an infectious diseases medical expert and thought leader, will review current COVID-19 treatment guidelines, the COVID-19 antiviral treatment landscape, and mechanistic and structural considerations of medicines targeting coronaviruses. To listen to the webcast and view the presentation slides, please visit https://investor.ligand.com/ir-calendar. To participate in the Q&A portion of the event, please dial (833) 325-0071 within the U.S. or (720) 405-1612 outside the U.S. and use Conference ID 4279228. Questions can also be submitted via email during the event to investors@ligand.com. The webcast will be archived on the Ligand website for 90 days following the event. About Matthew R. Davis, PharmD Dr. Davis obtained his Doctorate of Pharmacy from the University of Texas at Austin College of Pharmacy and completed post-graduate training at the University of California at Davis Medical Center specializing in infectious diseases, where he studied triazole pharmacokinetics/pharmacodynamics and toxicology. He is currently the infectious diseases clinical pharmacist at the Ronald Reagan UCLA Medical Center in Los Angeles. He serves on the UCLA COVID-19 Treatment Guidance Committee, which is responsible for developing and maintaining therapeutic guidelines for the institution. Additionally, he serves as the lead for the University of California System-wide Antimicrobial Stewardship Collaborative, a collaborative effort among five academic medical centers in the University of California system. He has lectured about preclinical and clinical data for remdesivir at international conferences and has published and presented reviews on its current and future roles in infection therapy. About Ligand Pharmaceuticals Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligands OmniAb technology platform is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. The Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. The Vernalis Design Platform (VDP) integrates protein structure determination and engineering, fragment screening and molecular modeling, with medicinal chemistry, to help enable success in novel drug discovery programs against highly challenging targets. Ab Initio technology and services for the design and preparation of customized antigens enable the successful discovery of therapeutic antibodies against difficult-to-access cellular targets. Icagen has established deep biological expertise focused on ion channels and transporters and has a strong track record in ion channel drug discovery from screening to lead optimization. Ligand has established multiple alliances, licenses and other business relationships with the worlds leading pharmaceutical companies including Amgen, Merck, Pfizer, Sanofi, Janssen, Takeda, Servier, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on Twitter @Ligand_LGND.

Answer: Ligand to Host Virtual Investor Day on October 20th